Industry News
News and Press Releases
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.
Neil Maresky, CEO Psyence Group | Spotlight Interview
Cardinal Capital Partners and MindHealth BioMed Receives CSE Conditional Listing Approval In this Spotlight interview, Neil Maresky, CEO Psyence Group talks with Psychedelic Finance about what spurred his interest in the [...]
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence Group Announces Private Placement
Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain
Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.
Covid-19 steepens the trajectory of an already booming functional mushroom market
Covid-19 steepens the trajectory of an already booming functional mushroom market The global functional mushroom market was valued at USD 25.4 billion in 2020, and it projected to reach a CAGR [...]
In conversation with Neil van Rij on Psyence’s magic mushrooms
Neil van Rij is Psyence’s resident mycologist. In this interview he sheds some light on the mushrooms Psyence is growing at its state-of-the-art facility in Lesotho and what these mushrooms will be used for.
The potential for psychedelics as part of palliative care: Louis Schwartzberg talks to Dr. Dingle Spence
Our Western culture teaches us to push grief away, push death away and we do everything we can to distract ourselves from dealing with terrible pain, whether it is physical pain, grief pain or fear of death. I really see the future of psychedelics in helping us deal with existential distress.
Psyence Group Announces Commencement Of Trading On OTCQB And DTC Eligibility Of Common Shares In The United States Under The Ticker “PSYGF”
We are pleased to announce that, effective today, Psyence common shares have been approved for trading on the OTCQB® Venture Market (the “OTCQB”) under the symbol “PSYGF”.
Dr Dingle Spence to speak at two conferences on psychedelics
Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.
Psyence completes its first official, validated harvest of psychedelic mushrooms
Psyence Group is one step closer to achieving British Standards Institute (BSI) certification , having completed its first official validated harvest of psychedelic mushrooms (psilocybe cubensis) at its federally-licensed facility In Lesotho, Southern Africa. The state-of-the-art facility has been built to GMP standards, is FDA registered and has been operational since January 2021.
Pure Psyence: A Joint Venture Sealed between Psyence Group and Pure Extracts
Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.
In Conversation With Dr Amza Ali on Palliative Care
Dr Amza Ali, neurologist and global medical director at Psyence shares some more light on this subject explaining what palliative care is, why it needs more attention and what Psyence’s vision and mission are when it comes to improving the access to and the effectiveness of palliative care globally.
The Diaries of a Psychedelic Exec : Episode 8
This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.
The Diaries of a Psychedelic Exec : Episode 7
Dr Amza Ali is a neurologist and the global medical director at Psyence. In this episode of the Diary of a Psychedelic Exec, Dr Ali shares his thoughts on palliative care, a key focus area for Psyence.
Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products
We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.
The Diaries of a Psychedelic Exec : Episode 6
Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.
Why Natural Psilocybin?
We believe that natural psilocybin offers multiple benefits for the long-term treatment of mental health conditions that may result from trauma. Plant-based and natural remedies are our preferred route as conscious consumers increasingly seek more natural treatments when it comes to supporting their mental wellbeing.
The Diaries of a Psychedelic Exec : Episode 5
It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.
Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial
Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.
The Diaries of a Psychedelic Exec : Episode 4
In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.
Psyence Group Announces Appointment of New Chief Executive Officer
Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.
Medicinal Mushrooms Of The Tsitsikamma Forest
This protected indigenous forest is the jewel of South Africa’s Garden Route, second only in popularity among foreign tourists to the Kruger National Park. It is also home to an incredible array of mushroom species.
World Psychedelics Day 2021
On 20 June 2021 we celebrate the inaugural World Psychedelic Day. This day has been set aside to recognise a new era of rational and informed perspectives on modern day psychedelics and traditional psychoactive plant medicines. To mark this day, we asked some of our team why they believe in the healing power of psychedelics and natural plant-based medicine.
Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
Psyence Group Announces a Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
The Diary of a Psychedelic CEO | Episode 03
I am a strong believer that in business, one always has to mitigate risk. Yes, we are focusing on psilocybin and doing some incredibly exciting work in this space, but parallel to this we are also building a business in mental health and mental wellness.
The Diary of a Psychedelic CEO | Episode 02
In this episode I share the story of Psyence and how it came into being. From receiving a full license to cultivate, process, import, produce and export Psilocybin mushrooms just over a year ago, to designing and building out our commercial facility, a lot has been achieved in a short time.
The Psyence Group Announces its Formal Entry Into Jamaica
Psyence establishes Psyence Jamaica as part of its strategy to develop standardized nutraceutical and pharmaceutical psychedelic products in Jamaica for the treatment of psychological traumas.
The Diary of a Psychedelic CEO | Episode 01
It’s been an exciting four months since we listed Psyence on the CSE January 2021. My team and I have been hard at work since then, perfecting our strategy, commencing operations, product development and making sure that we are hyper focused on what we are trying to achieve.
We Are Hiring – Commercial General Manager – South Africa
We Are Hiring - Commercial General Manager - South Africa
Psyence Group Corporate Update
Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.
Advancing the extraordinary therapeutic potential of natural psilocybin
Psyence Group is advancing the extraordinary therapeutic potential of natural psilocybin Proactive sat down with CEO Aufrichtig, a trained chartered accountant, to learn more about the Psyence Group’s clear path to revenue and value creation. [...]
10 things you may not know about know about Psilocybin
At first glance Psilocybe cubenis doesn’t look that different to other mushrooms, there is nothing about their appearance that makes them particularly special. Yet, researchers around the world are growingly increasingly interested in the magic [...]
How We Grow Our Psilocybin Mushrooms
At Psyence we have sourced the world's best genetics, and coupled that with world leading expertise in the field of mycology, to produce the highest quality mushrooms. Our process is complex, but refined.
Did You Know That Psilocybin Mushrooms Are Rare?
Psilocybin is an alkaloid found in the fruits of some fungi. These fungi are rare in the wild requiring skill to find. There are various mushroom genus that contain psilocybin namely Psilocybe, Gymnopilus, Inocybe, Galerina, [...]
JV Signed With Pure Extracts
Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.
Psyence Cultivation And Harvesting Psilocybin In Lesotho
The Psyence team shares details on our existing cultivation and harvesting operations in our federally-licensed cultivation facility in Lesotho, Southern Africa. Psyence (CSE:PSYG) is a life science biotechnology company, pioneering the [...]
Partnership with Base Pair Health announced
Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team TORONTO, ON/ March 5, 2021 / Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce [...]
Functional mushroom brand, “GOODMIND”, launched
Psyence Group Launches It's Functional Mushroom Brand, "GoodMind" And Makes Board Changes. Toronto, Canada/, Cape Town March 4, 2021 – Psyence Group Inc., a leading platform in [...]
Collaboration with Jamaican retreat provider to conduct observational study
Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider to Conduct Observational Study Toronto, Canada/Kingston, Jamaica February 10, 2021 – Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased [...]
Psyence presents at Canaccord Genuity Conference
Press Release: Psyence Group Presenting at Canaccord Genuity Conference “New Paradigms & Treatment Approaches in Mental Health” TORONTO, ON / February 3, 2021 / Psyence Group Inc. (CSE: PSYG) (“Psyence” or [...]
First Cultivation of medical psilocybin mushrooms completed
Psyence Group Competes First Cultivation Cycle of Medical Psilocybin Mushrooms at its Commercially Licensed Facility TORONTO, ON / January 29, 2021 / Psyence Group Inc. (“Psyence” or the “Company”) is pleased [...]
Psyence Group to Commence Trading (CSE : PSYG)
Psyence Group to Commence Trading (CSE: PSYG) on January 27, 2021 TORONTO, ON / January 26, 2021 / Psyence Group Inc. (“Psyence” or the “Company”), is pleased to announce that its [...]
CSE conditional listing approval received
Cardinal Capital Partners and MindHealth BioMed Receives CSE Conditional Listing Approval Toronto, Ontario-- - Cardinal Capital Partners Inc. (the "Company" or "Cardinal") and MindHealth Biomed Corp. ("MindHealth", and together with Cardinal, [...]
News and Press Releases
Psyence looks to expand capital market opportunities in the UK and Europe
TORONTO, DATE, 2022 – Psyence Group Inc. (CSE: PSYG | OTCQB: PSYGF) (“Psyence” or the “Company”), a life science biotechnology company pioneering the use of natural psychedelics in mental health and well-being, announces that it is investigating capital market opportunities to access a broader pool of United Kingdom (“UK”) and European investors. This includes a potential dual listing in the UK.
Neil Maresky, CEO Psyence Group | Spotlight Interview
Cardinal Capital Partners and MindHealth BioMed Receives CSE Conditional Listing Approval In this Spotlight interview, Neil Maresky, CEO Psyence Group talks with Psychedelic Finance about what spurred his interest in the [...]
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence to Present at the H.C Wainwright 2nd Annual Psychedelics Conference December 6
Psyence Group Announces Private Placement
Psyence announces that it is commencing a non-brokered private placement offering of up to CAD$2,000,000 of unsecured convertible promissory notes (the “Notes”).
Psyence Group Functional Mushroom Brand “GOODMIND™” Commences National Roll-Out In South Africa’s Largest Coffee Retail Chain
Psyence is pleased to announce that its joint venture functional mushroom brand GOODMINDTM has partnered with one of Africa’s largest coffee retail chains, “vida e caffè”, to commence the rollout of its GOODMINDTM functional mushroom brand in select vida e caffè’s coffee shops in South Africa.
Psyence Group Invited as First Psychedelic Company to present at the 15th-Annual Global Wellness Summit
Psyence’s Head of Corporate Social Responsibility, Mary-Elizabeth Gifford, will host an in-person keynote conversation with Rick Doblin, PhD, Founder and Executive Director of the Multidisciplinary Association for Psychedelic Studies (MAPS) on the future of Psychedelics and Healing.
Covid-19 steepens the trajectory of an already booming functional mushroom market
Covid-19 steepens the trajectory of an already booming functional mushroom market The global functional mushroom market was valued at USD 25.4 billion in 2020, and it projected to reach a CAGR [...]
In conversation with Neil van Rij on Psyence’s magic mushrooms
Neil van Rij is Psyence’s resident mycologist. In this interview he sheds some light on the mushrooms Psyence is growing at its state-of-the-art facility in Lesotho and what these mushrooms will be used for.
The potential for psychedelics as part of palliative care: Louis Schwartzberg talks to Dr. Dingle Spence
Our Western culture teaches us to push grief away, push death away and we do everything we can to distract ourselves from dealing with terrible pain, whether it is physical pain, grief pain or fear of death. I really see the future of psychedelics in helping us deal with existential distress.
Psyence Group Announces Commencement Of Trading On OTCQB And DTC Eligibility Of Common Shares In The United States Under The Ticker “PSYGF”
We are pleased to announce that, effective today, Psyence common shares have been approved for trading on the OTCQB® Venture Market (the “OTCQB”) under the symbol “PSYGF”.
Dr Dingle Spence to speak at two conferences on psychedelics
Dr. Spence, an oncologist, palliative care specialist, and health justice activist will speak at the EndWell Conference – “The End in Mind – Psychedelic Medicines & Ending Well” taking place virtually on Thursday, October 14, 2021. Dr. Spence is also a featured speaker at the “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms” taking place virtually on Friday, Saturday, and Sunday October 15-17th 2021.
Psyence completes its first official, validated harvest of psychedelic mushrooms
Psyence Group is one step closer to achieving British Standards Institute (BSI) certification , having completed its first official validated harvest of psychedelic mushrooms (psilocybe cubensis) at its federally-licensed facility In Lesotho, Southern Africa. The state-of-the-art facility has been built to GMP standards, is FDA registered and has been operational since January 2021.
Pure Psyence: A Joint Venture Sealed between Psyence Group and Pure Extracts
Our Joint Venture with Pure Extracts, "Pure Psyence", is an important milestone for Psyence Group. Pure Psyence will develop nature-derived psilocybin extracts, and advanced psilocybin formulations, for the long-term treatment of psychological trauma and its mental health consequences. The JV's combined expertise in formulation development of psychoactive compounds will enable Pure Psyence to produce stable and effective psilocybin medicinal products and work towards making psilocybin more accessible.
In Conversation With Dr Amza Ali on Palliative Care
Dr Amza Ali, neurologist and global medical director at Psyence shares some more light on this subject explaining what palliative care is, why it needs more attention and what Psyence’s vision and mission are when it comes to improving the access to and the effectiveness of palliative care globally.
The Diaries of a Psychedelic Exec : Episode 8
This week we continue to hear from Dr Amza Ali, neurologist and global medical director at Psyence about palliative care, and Psyence’s vision for making a positive impact on the lives of people suffering from serious illnesses.
The Diaries of a Psychedelic Exec : Episode 7
Dr Amza Ali is a neurologist and the global medical director at Psyence. In this episode of the Diary of a Psychedelic Exec, Dr Ali shares his thoughts on palliative care, a key focus area for Psyence.
Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products
We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.
The Diaries of a Psychedelic Exec : Episode 6
Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.
Why Natural Psilocybin?
We believe that natural psilocybin offers multiple benefits for the long-term treatment of mental health conditions that may result from trauma. Plant-based and natural remedies are our preferred route as conscious consumers increasingly seek more natural treatments when it comes to supporting their mental wellbeing.
The Diaries of a Psychedelic Exec : Episode 5
It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.
Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial
Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.
The Diaries of a Psychedelic Exec : Episode 4
In this week's diary I reflect on the impact of trauma in our lives following an unexpected medical emergency at home. This has fuelled my passion for what we are doing here at Psyence and the positive impact we could have on the lives of so many people.
Psyence Group Announces Appointment of New Chief Executive Officer
Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.
Medicinal Mushrooms Of The Tsitsikamma Forest
This protected indigenous forest is the jewel of South Africa’s Garden Route, second only in popularity among foreign tourists to the Kruger National Park. It is also home to an incredible array of mushroom species.
World Psychedelics Day 2021
On 20 June 2021 we celebrate the inaugural World Psychedelic Day. This day has been set aside to recognise a new era of rational and informed perspectives on modern day psychedelics and traditional psychoactive plant medicines. To mark this day, we asked some of our team why they believe in the healing power of psychedelics and natural plant-based medicine.
Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
Psyence Group Announces a Collaboration with the Scientific Research Council (SRC) of Jamaica for Psilocybin Product Development
The Diary of a Psychedelic CEO | Episode 03
I am a strong believer that in business, one always has to mitigate risk. Yes, we are focusing on psilocybin and doing some incredibly exciting work in this space, but parallel to this we are also building a business in mental health and mental wellness.
The Diary of a Psychedelic CEO | Episode 02
In this episode I share the story of Psyence and how it came into being. From receiving a full license to cultivate, process, import, produce and export Psilocybin mushrooms just over a year ago, to designing and building out our commercial facility, a lot has been achieved in a short time.
The Psyence Group Announces its Formal Entry Into Jamaica
Psyence establishes Psyence Jamaica as part of its strategy to develop standardized nutraceutical and pharmaceutical psychedelic products in Jamaica for the treatment of psychological traumas.
The Diary of a Psychedelic CEO | Episode 01
It’s been an exciting four months since we listed Psyence on the CSE January 2021. My team and I have been hard at work since then, perfecting our strategy, commencing operations, product development and making sure that we are hyper focused on what we are trying to achieve.
We Are Hiring – Commercial General Manager – South Africa
We Are Hiring - Commercial General Manager - South Africa
Psyence Group Corporate Update
Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to provide the following corporate update on its three clear paths to revenue and value creation namely: Psyence Production, Psyence Therapeutics and Psyence Function.
Advancing the extraordinary therapeutic potential of natural psilocybin
Psyence Group is advancing the extraordinary therapeutic potential of natural psilocybin Proactive sat down with CEO Aufrichtig, a trained chartered accountant, to learn more about the Psyence Group’s clear path to revenue and value creation. [...]
10 things you may not know about know about Psilocybin
At first glance Psilocybe cubenis doesn’t look that different to other mushrooms, there is nothing about their appearance that makes them particularly special. Yet, researchers around the world are growingly increasingly interested in the magic [...]
How We Grow Our Psilocybin Mushrooms
At Psyence we have sourced the world's best genetics, and coupled that with world leading expertise in the field of mycology, to produce the highest quality mushrooms. Our process is complex, but refined.
Did You Know That Psilocybin Mushrooms Are Rare?
Psilocybin is an alkaloid found in the fruits of some fungi. These fungi are rare in the wild requiring skill to find. There are various mushroom genus that contain psilocybin namely Psilocybe, Gymnopilus, Inocybe, Galerina, [...]
JV Signed With Pure Extracts
Psyence Group Inc. (CSE: PSYG) (“Psyence”), and Pure Extracts Technologies Corp. (CSE: PULL) (OTC: PRXTF) (XFRA: A2QJAJ) (“Pure Extracts”) and are pleased to announce the signing of a Letter of Intent (“LOI”) to form a Joint Venture (the “JV”) to develop superior techniques for the extraction of psilocybin from psychedelic mushrooms, as well as the development of advanced formulations containing psilocybin for the long-term treatment of psychological trauma and its mental health consequences.
Psyence Cultivation And Harvesting Psilocybin In Lesotho
The Psyence team shares details on our existing cultivation and harvesting operations in our federally-licensed cultivation facility in Lesotho, Southern Africa. Psyence (CSE:PSYG) is a life science biotechnology company, pioneering the [...]
Partnership with Base Pair Health announced
Psyence Group Announces Partnership With Base Pair Health and Strengthens Management Team TORONTO, ON/ March 5, 2021 / Psyence Group Inc. (CSE: PSYG) (“Psyence” or the “Company”) is pleased to announce [...]
Functional mushroom brand, “GOODMIND”, launched
Psyence Group Launches It's Functional Mushroom Brand, "GoodMind" And Makes Board Changes. Toronto, Canada/, Cape Town March 4, 2021 – Psyence Group Inc., a leading platform in [...]
Collaboration with Jamaican retreat provider to conduct observational study
Psyence Group Signs Collaboration Agreement with Leading Jamaican Psilocybin Retreat Provider to Conduct Observational Study Toronto, Canada/Kingston, Jamaica February 10, 2021 – Psyence Group Inc., through its wholly-owned subsidiary Psyence Therapeutics Corp. (“Psyence”), is pleased [...]
Psyence presents at Canaccord Genuity Conference
Press Release: Psyence Group Presenting at Canaccord Genuity Conference “New Paradigms & Treatment Approaches in Mental Health” TORONTO, ON / February 3, 2021 / Psyence Group Inc. (CSE: PSYG) (“Psyence” or [...]
First Cultivation of medical psilocybin mushrooms completed
Psyence Group Competes First Cultivation Cycle of Medical Psilocybin Mushrooms at its Commercially Licensed Facility TORONTO, ON / January 29, 2021 / Psyence Group Inc. (“Psyence” or the “Company”) is pleased [...]
Psyence Group to Commence Trading (CSE : PSYG)
Psyence Group to Commence Trading (CSE: PSYG) on January 27, 2021 TORONTO, ON / January 26, 2021 / Psyence Group Inc. (“Psyence” or the “Company”), is pleased to announce that its [...]
CSE conditional listing approval received
Cardinal Capital Partners and MindHealth BioMed Receives CSE Conditional Listing Approval Toronto, Ontario-- - Cardinal Capital Partners Inc. (the "Company" or "Cardinal") and MindHealth Biomed Corp. ("MindHealth", and together with Cardinal, [...]
Psyence In The News
Psyence Group’s functional mushroom brand to be sold in South Africa’s largest coffee retail chain
Psyence Group begins trading on the OTCQB platform in New York to satisfy investor demand
Psyence Group Inc CFO Warwick Corden-Lloyd joined Proactive New York to discuss the group’s plan to increase exposure to US investors by beginning to trade on the OTCQB Venture Market platform. In addition, the Toronto-based firm said it has applied for Depository Trust Company (DTC) eligibility to simplify the trading process in the US. Corden-Lloyd says Psyence will have a presence at two upcoming conferences to discuss its recent advancements: the “The End in Mind – Psychedelic Medicines & Ending Well” and “Fantastic Fungi Global Summit – The Transformational Power of Mushrooms.”
Psyence Group launches its functional mushroom products under the GOODMIND banner in South Africa
Psyence Group Inc (CSE:PSYG)’s Tony Budden caught up with Proactive New York to discuss the the international biotechnology company with operations in South Africa’s launch of its range of functional mushroom products under the GOODMIND banner.
In this interview with Proactive Investors, Dr. Neil Maresky talks about his appointment as CEO of Psyence Group.
He shares insights about his career, including spending more than a decade at AstraZeneca Canada as Vice President of Scientific Affairs. Dr. Maresky, a South African trained doctor, tells Proactive about his motivation to join Psyence, stating that it is because of its ability to potentially impact mental health including depression, anxiety, PTSD, and end-of-life care.
Take a listen here.
Psyence Group ‘delighted’ to reach psilocybin product development agreement with Jamaican government
Interested in Psyence’s collaboration with the Jamaican government’s Scientific Research Council (SRC)? Take a listen to the Proactive Investors interview with Psyence CEO Jody Aufrichtig and learn more about the agreement which will consist of three key initiatives: developing psilocybin-based nutraceuticals; identifying and collecting Jamaica’s psychedelic and psychoactive mushrooms, and sorting protocols to optimize spawn production of rare psychedelic mushroom species.
Psychedelic Finance chats to Psyence CEO Jody Aufrichtig
19 January 2021
Find out why our CEO believes in psychedelics, what Psyence stands for and how the lessons Jody learnt in the cannabis industry are helping him navigate the psychedelics opportunity in this in depth Q&A with Psychedelic Finance.
Jody Aufrichtig in conversation
with the CSE’s
Barrington Miller
19 February 2021
Psyence joined the CSE’s Barrington Miller to tell our story and share what we believe sets Psyence apart from other companies in this space: we are licensed, operational and global. Want to know more?
Take a look at this video: